Suchergebnisse - "Cahn, Avivit"

PubPharm (145)

61

SGLT2抑制剂用于心血管事件的一级预防

enthalten in: Journal of Diabetes | 2020

von Raz, I. | Cernea, S. | Cahn, A.

62

The SONAR study-is there a future for endothelin receptor antagonists in diabetic kidney disease?

enthalten in: Annals of translational medicine | 2019

von Cahn, A. | Cernea, S. | Raz, I.

CommentOn: Lancet. 2019 May 11;393(10184):1937-1947. - PMID 30995972

63

Association of Inpatient Glucose Measurements With Amputations in Patients Hospitalized With Acute Diabetic Foot

enthalten in: The Journal of clinical endocrinology and metabolism | 2019

von Peled, S. | Pollack, R. | Elishoov, O. | +2

64

Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction : Observations From the SAVOR-TIMI 53 Trial

enthalten in: Circulation | 2019

von Bergmark, B. | Bhatt, D. | McGuire, D. | +10

CommentIn: Circulation. 2020 Jan 28;141(4):e55-e56. - PMID 31986096

65

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes : an analysis from the DECLARE-TIMI 58 randomised trial

enthalten in: The lancet. Diabetes & endocrinology | 2019

von Mosenzon, O. | Wiviott, S. | Cahn, A. | +18

CommentIn: Lancet Diabetes Endocrinol. 2019 Aug;7(8):585-587. - PMID 31196816

66

Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus : Observations from SAVOR-TIMI 53

enthalten in: Clinical chemistry | 2019

von Zelniker, T. | Morrow, D. | Mosenzon, O. | +9

67

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

enthalten in: Circulation | 2019

von Kato, E. | Silverman, M. | Mosenzon, O. | +20

CommentIn: Circulation. 2019 May 28;139(22):2537-2541. - PMID 30882236

68

Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction

enthalten in: Circulation | 2019

von Furtado, R. | Bonaca, M. | Raz, I. | +16

CommentIn: Circulation. 2019 May 28;139(22):2537-2541. - PMID 30882236

69

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus

enthalten in: Circulation | 2019

von Zelniker, T. | Wiviott, S. | Raz, I. | +12

CommentIn: Kidney Int. 2019 Jul;96(1):8-10. - PMID 31229049

70

Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors : Real-world data analysis

enthalten in: Diabetes, obesity & metabolism | 2019

von Cahn, A. | Melzer-Cohen, C. | Pollack, R. | +2